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http://www.biomedcentral.com/1471-2474/15/64RESEARCH ARTICLE Open AccessEfficacy of zoledronic acid for chronic low back
pain associated with Modic changes in magnetic
resonance imaging
Katri Koivisto1, Eero Kyllönen1, Marianne Haapea2,3, Jaakko Niinimäki2, Kaj Sundqvist1, Timo Pehkonen4,
Seppo Seitsalo5, Osmo Tervonen2 and Jaro Karppinen1,6,7*Abstract
Background: Modic changes (MC) are associated with low back pain (LBP), but effective treatments are lacking.
The aim of this randomized, placebo-controlled, double-blinded trial was to evaluate the efficacy of zoledronic acid
(ZA) for chronic LBP among patients with MC in magnetic resonance imaging (MRI).
Methods: Inclusion criteria were LBP lasting ≥3 months, with an intensity of ≥6 on a 10-cm VAS or an Oswestry
Disability Index (ODI) of ≥30%, and MC in MRI. Patients were randomized into single intravenous infusion of ZA 5 mg
(n = 20), or placebo (n = 20) groups. The primary outcome was LBP intensity, secondary outcomes leg pain intensity,
ODI, health-related quality of life (RAND-36), lumbar flexibility, sick leaves and use of pain medication. The treatment
differences at one month and one year were analysed using ANCOVA with adjustment for the baseline score.
Results: The mean difference (MD) between the groups in the primary outcome, intensity of LBP, was 1.4 (95%
confidence intervals (CI) 0.01 to 2.9) in favour of ZA at one month. We observed no significant between-group
difference in the intensity of LBP at one year (MD 0.7; 95% CI −1.0 to 2.4) or in secondary outcomes at any time point
except that 20% of patients in the ZA group used non-steroidal anti-inflammatory drugs at one year compared to
60% in the placebo group (P = 0.022). Acute phase reactions (fever, flu-like symptoms, arthralgia) emerged in 95% of
the patients in the ZA group, compared to 35% in the placebo group.
Conclusions: ZA was effective in reducing the intensity of LBP in the short term and in reducing the use of NSAIDs
within the time span of one year among patients with chronic LBP and MC confirmed in MRI. Although the results
seem encouraging, larger studies are required to analyse the effectiveness and safety of ZA for patients with MC.
Trial registration: ClinicalTrial.gov identifier NCT01330238.
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Modic changes (MC) are pathological vertebral endplate
and bone marrow changes visible in magnetic resonance
imaging (MRI). Three different types of MC have been
described; Type I (M1) lesions, considered to be the earli-
est and the most active stage in the process of MC evolu-
tion, are associated with vascular granulation tissue within* Correspondence: jaro.karppinen@ttl.fi
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unless otherwise stated.the subchondral bone, whereas Type II (M2) lesions re-
flect fatty replacement of the red bone marrow [1]. The
presence of mixed-type MC such as I/II (M1/2) has also
been reported [2,3]. These are thought to reflect the con-
version of MC from one type to another, representing
different stages of the same pathological process [3-6].
MC are considered clinically relevant due to their as-
sociation with chronic low back pain (LBP) [7-10]. This
association was also found in a systematic literature
review [11]. In general, M1 changes have been more fre-
quently reported as being related to LBP than other MC
types [7,9,12,13]. Moreover, the persistence of the M1
component correlates with persistence of symptoms [13].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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questioned, as in prospective studies, MC were not indi-
cated as having any prognostic role in future low back
symptoms [14,15].
A limited number of therapeutic options have been
evaluated for MC, as only two randomized trials on the
treatment of MC have been published so far: a 100-day
amoxicillin-clavulanate treatment was reported to have
induced a marked improvement in LBP in chronic LBP
patients with a M1 change after disc herniation [16],
whereas another trial found no difference on the effects
of rest and exercise on LBP with MC [17]. Bisphospho-
nates are considered a potential treatment option for
MC as bone marrow lesions are less commonly observed
in patients using alendronate [18]. Zoledronic acid (ZA)
is a potent bisphosphonate, which can be administered
intravenously once a year and has been shown to sup-
press osteoclast recruitment, differentiation and func-
tion, as well as promoting apoptosis [19]. ZA has been
shown to reduce the progression of bone oedema in
MRI with concordant improvement in clinical measures
of disease activity among patients with psoriatic arthritis
[19], and improvement in knee symptoms and bone
marrow lesion size among patients with knee osteoarth-
ritis [20]. The objective of our study was to evaluate the
efficacy of a single intravenous infusion of 5 mg ZA in
comparison with intravenous placebo infusion among
patients with chronic LBP and MC in MRI.
Methods
Study design and selection of patients
This study was an investigator-initiated, single-centre,
double-blinded, randomized, placebo-controlled clinical
trial. Enrolled patients were referred from primary health
care units to Oulu University Hospital, a tertiary care
unit, where they were screened for eligibility by the prin-
cipal investigator (KK). Inclusion criteria were low back
symptoms for at least three months, an LBP intensity of
at least six (6) on a 10-cm Visual Analog Scale (VAS) or
an Oswestry Disability Index (ODI) of at least 30% [21],
and an M1, mixed M1/2 or M2 in MRI performed within
six months at most prior to enrolment. MRI scans were
classified as previously described [9]; M1 lesions showing
low signal intensity (SI) on T1-weighted (T1W) and high
SI on T2-weighted (T2W) images, M2 lesions showing
high SI on both T1W and T2W, and M3 showing low SI
on both T1W and T2W.
The exclusion criteria included renal impairment with
reduced creatinine clearance defined as an estimated
glomerular filtration rate (eGFR) below 40 ml/min,
hypocalcaemia, known hypersensitivity to ZA or other
bisphosphonates or ingredients of the infusion product,
the presence of red flags, nerve root entrapment and
willingness for early retirement. Premenopausal womenof childbearing potential were also excluded. Blood sam-
ples were taken prior to the infusion to assess the serum
concentration of calcium and creatinine. The clinical
examination included medical history and clinical as-
sessment of lumbar flexibility, tendon signs, and motor
and sensory testing.
The Oulu University Hospital ethics committee ap-
proved the study protocol. All patients provided written
informed consent before any study-specific procedures
were performed. This study was registered (Clinical-
Trials.gov, unique identifier NCT01330238) prior to the
initiation of enrolment and was conducted in accordance
with the principles of the Declaration of Helsinki.Treatment intervention
Participants were recruited between November 2008 and
March 2011. After confirmation of eligibility patients
were randomized to receive a single intravenous infusion
of 5 mg ZA in 100 ml saline (n = 20) or 100 ml saline as
placebo (n = 20) over a 15-minute period. The principal
investigator (KK) administered the infusions, assisted by
a nurse.
Before administration of the infusion, all patients re-
ceived oral ibuprofen 600 mg or paracetamol 1 g as
prophylaxis for potential acute phase reactions such as
flu-like symptoms, headache or fever. Patients were
advised to use the same medication should post-dose
symptoms appear. They all also received 100 000 units
of Vitamin D (Vigantol®) orally to prevent hypocalcae-
mia. Information on use of the concomitant medication
and hospital admissions were recorded. Blood samples
were taken for the assessment of safety, inflammatory
mediators and markers of bone turnover at baseline,
one month and one year.Treatment assignment
A master randomization list was generated by a com-
puter in blocks of eight, containing four placebo and
four ZA allocations in random order. Patients were
assigned a unique randomization number according to
the order of inclusion. Patients, the principal investiga-
tor performing the screening and follow-up assess-
ments, the nurse, the radiologist evaluating the MRI
scans, and the statistician performing the analysis were
blinded to the treatment allocation. The ZA and placebo
were supplied in identical bottles by Novartis Pharma,
Basel, Switzerland, to a pharmacist who prepared the
intravenous solutions according to the allocation list
and supplied the solution without revealing the treatment
code. The treatment allocation was concealed in sealed
envelopes until completion of the one-year follow-up of
the last patient and the codes were opened only after the
statistical analysis.
Figure 1 Study flowchart.
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Clinical assessments were performed 14 days before en-
rolment (screening visit), and follow-up visits at one
month and one year after the infusion. The primary out-
come was the change in the intensity of LBP on VAS.
Secondary outcomes included leg pain intensity, ODI,
health-related quality of life assessed with RAND-36
[22], patient-reported sick leaves and lumbar flexibility.
These outcome measures were assessed at baseline and
at each follow-up. Lumbar flexibility was evaluated using
the fingers-to-floor and trunk side bending measures (in
cm). Pain medication use was inquired about during the
follow-up visits.
Safety parameters
The occurrence of any adverse effects was observed
during the infusion and inquired about at each of the
follow-up visits.
Statistical analysis
Baseline characteristics of demographics and symptoms
were described using mean values (with standard devi-
ation, SD), frequencies (with proportions) or median
values (with interquartile range). Treatment effects at
one month and one year were analysed by comparing
the change in the outcomes of the treatment groups
(mean, 95% confidence interval (CI)) by using the inde-
pendent samples t-test (crude p-values for group differ-
ences), and analysis of covariance (ANCOVA) with
adjustment for the baseline score. We also adjusted the
treatment difference for age and gender but the point
estimates did not change considerably - only the confi-
dence intervals widened. RAND-36 was analysed by
using the sum of all items (total), and separate sums of
physical and psychiatric items. The sums were standard-
ized to follow normal distribution with a mean of 50 and
standard deviation of 10 (N(50,10)). We also analysed
the percentage of patients undergoing a 20% relative im-
provement and the proportion of patients reaching a
VAS score of 40 or less in the primary outcome, patient
acceptable symptom state (PASS) as recommended by
Tubach et al. [23]. We used IBM SPSS Statistics 21.0
(IBM Corp., Armonk, NY) for statistical analyses, and
considered p-values of <0.05 statistically significant.
Results
The study population
A total of 98 patients were screened for the study. More
than half of them, 58 patients, were excluded as they did
not meet the inclusion criteria (n = 35), refused to par-
ticipate (n = 16), or had kidney stones (n = 2), depression
(n = 2), dental problems (n = 1), malignancy (n = 1) or
hyperparathyreosis (n = 1). All 40 enrolled, eligible pa-
tients completed the one-year follow-up (Figure 1).The clinical characteristics of study participants at base-
line are displayed in Table 1. The mean LBP duration was
293 days, initial LBP intensity on VAS 6.7, leg pain on
VAS 2.9 and the ODI score was 32%. Altogether 19 pa-
tients in the ZA group and 18 in the placebo group had a
mixed-type M1/2 lesion. MC were most commonly (70%)
situated at L4/5 or L5/S1. The ZA and placebo groups
were similar as regards the demographic and background
characteristics of all patients at baseline, although there
were numerically more men (15 vs. 11) in the ZA group
than in the placebo group (Table 1).Treatment differences
The mean difference (MD) between the treatment groups
in the primary outcome, intensity of LBP, significantly
favoured ZA at one month (MD 1.4; 95% CI 0.01 to 2.9)
while at one year no significant difference was observed
(MD 0.7; 95% CI −1.0 to 2.4; Table 2). The proportion of
patients with at least 20% improvement in intensity of
LBP and PASS both favoured the ZA treatment at one
month: ZA 55% vs. placebo 25% (p = 0.105) and ZA 50%
vs. placebo 20% (p = 0.096), respectively.
Of the secondary outcomes, the improvement in ODI,
favored non-significantly ZA at 1 month, the adjusted
between-group difference being 6.0% (95% CI −0.6 to
13), but not at one year (Table 2). Similarly, side bending
(to right and left) non-significantly favoured the ZA
treatment at one month but not at one year (Table 2).
We observed no differences between the treatment groups
at any time point in leg pain intensity (Table 2), total
RAND-36, or in the physical and mental components of
RAND-36 (Table 3).
At baseline, there were no differences in self-reported
use of non-steroidal anti-inflammatory drugs (NSAIDs)
between the treatment groups, whereas at one year, only
20% of patients in the ZA group used NSAIDs versus
60% in the placebo group (P = 0.022). No significant
Table 1 Baseline characteristics of study population according to treatment group
Characteristics Zoledronic acid Placebo
n = 20 n = 20
Sex, n (%) men 15 (75) 11 (55)
Age, mean (SD) years 49 (9.3) 51 (7.3)
Smoking, n (%) regular smokers* 5 (25) 6 (30)
BMI, mean (SD) kg/m 26 (3.3) 27 (3.2)
Workload, n (%)
-Sedentary work with limited walking 4 (20) 4 (22)
-Fairly light work with considerable walking but no lifting or carrying heavy objects 4 (20) 3 (17)
-Fairly strenuous work with walking and lifting heavy objects or climbing stairs or uphil 8 (40) 6 (33)
-Very strenuous work with lifting or carrying heavy objects such as shovelling, digging
or hammering
4 (20) 5 (28)
Type of worst MC-lesion**, n
Type I 1 1
Type I/II 19 18
Type II 0 1
MC at two or more levels, n (%) 7 (35) 4 (20)





Duration of LBP, median (IQ range) days 330 (200, 365) 315 (270, 365)
Intensity of LBP, mean (SD)*** 6.6 (1.4) 6.8 (1.6)
Duration of leg pain, median (IQ range) days 50 (0, 100) 36 (0, 160)
Intensity of leg pain, mean (SD)*** 3.0 (3.1) 2.9 (2.3)
Oswestry Disability Index, %, Mean (SD) 30 (11) 35 (10)
Duration of sick leave during the past year, median (IQ range) days 14 (0, 48) 18 (1, 181)
RAND-36, mean (SD) 50 (8) 50 (7)
RAND-36 physical component, mean (SD) 51 (8) 49 (8)
RAND-36 mental component, mean (SD) 51 (8) 49 (9)
BMI = Body Mass Index, MC =Modic change, LBP = low back pain, SD = standard deviation, IQ = inter-quartile.
*Smoking at least one cigarette/day.
**If different types of MC at two or more levels, classification is based on the assumed severity of the type, i.e. Type I > mixed Type I/II > Type II.
***Assessed using a 10-cm Visual Analogue Scale (VAS).
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sick leave (data not shown).
Safety parameters
Reported adverse events (AE) were common and occurred
more frequently in the ZA group, especially immediately
after the infusion. AEs were mostly mild in nature
(Table 4). Despite prophylaxis, acute post-infusion phase
reactions (fever, headache, myalgia, arthralgia, pain, nau-
sea and flu-like symptoms) were observed in 19/20 pa-
tients in the ZA vs. 7/20 patients in the placebo group. As
expected, the majority of the acute phase reactions were
of mild to moderate severity as rated by the investigatorand typically resolved within three days of onset. One
event met the criteria for serious adverse effect (SAE) in
the ZA group; a male patient had sinusitis requiring tem-
porary hospitalization after the infusion.
Discussion
A single intravenous infusion of 5 mg ZA resulted in a
greater improvement in LBP intensity at one month.
Furthermore, the patients receiving ZA reported NSAID
use at one year significantly less often than those in the
placebo group. Overall, the improvements in most of the
evaluated parameters were greater in the ZA group
throughout the follow-up period. Adverse events were
Table 2 Low back symptoms and lumbar flexibility at baseline, one month and 12 months according to treatment
group and between group comparisons of difference from baseline to one month and 12 months
Mean (SD) original values Mean (SD) change Unadjusted analyses Adjusted analyses
ZA Placebo ZA Placebo Difference P Difference P*
n = 20 n = 20 (95% CI) (95% CI)
Intensity of LBP
Baseline 6.6 (1.4) 6.8 (1.6)
1 month 4.3 (2.3) 5.8 (2.2) −2.2 (2.7) −0.9 (2.1) 1.3 (−0.2 to 2.8) 0.097 1.4 (0.01 to 2.9) 0.049
12 months 3.8 (2.5) 4.6 (2.9) −2.8 (2.9) −2.2 (2.5) 0.6 (−1.1 to 2.4) 0.474 0.7 (−1.0 to 2.4) 0.387
Intensity of leg paina
Baseline 3.0 (3.1) 2.9 (2.3)
1 month 2.0 (2.3) 3.0 (2.4) −0.6 (2.4) 0.1 (2.6) 0.8 (−0.9 to 2.4) 0.367 0.8 (−0.6 to 2.2) 0.237
12 months 2.1 (2.8) 2.7 (2.6) −0.9 (3.4) −0.3 (3.0) 0.6 (−1.5 to 2.7) 0.573 0.5 (−1.3 to 2.2) 0.573
Oswestry disability index, %
Baseline 30 (11) 35 (10)
1 month 24 (10) 33 (13) −5.9 (11) −1.7 (9.7) 4.3 (−2.5 to 11) 0.212 6.0 (−0.6 to 13) 0.071
12 months 25 (13) 33 (15) −5.0 (15) −1.9 (12) 3.1 (−5.6 to 12) 0.475 5.1 (−3.4 to 14) 0.231
Fingers-to-floor, cm
Baseline 23 (19) 19 (18)
1 month 17 (17) 19 (17) −5.1 (20) −0.1 (8.3) 5.0 (−4.8 to 15) 0.306 3.6 (−5.0 to 12) 0.403
12 months 16 (16) 20 (19) −6.3 (23) 0.9 (11) 7.1 (−4.3 to 18) 0.215 5.3 (−4.5 to 15) 0.277
Sidebending to right, cm
Baseline 14.1 (4.9) 13.8 (7.2)
1 month 15.7 (5.9) 13.3 (6.9) 1.5 (4.7) −0.5 (2.2) −2.0 (−4.3 to 0.4) 0.101 −2.0 (−4.4 to 0.3) 0.087
12 months 15.7 (5.6) 13.8 (6.5) 1.6 (4.8) −0.1 (3.5) −1.6 (−4.3 to 1.1) 0.227 −1.7 (−4.2 to 0.8) 0.180
Sidebending to left, cm
Baseline 15.0 (5.4) 13.3 (5.5)
1 month 16.1 (5.3) 12.8 (5.9) 1.1 (3.0) −0.5 (2.2) −1.5 (−3.2 to 0.1) 0.072 −1.7 (−3.4 to 0.0) 0.051
12 months 16.2 (6.7) 13.7 (5.7) 1.2 (5.3) 0.5 (3.2) −0.7 (−3.5 to 2.1) 0.601 −1.0 (−3.8 to 1.8) 0.458
SD = standard deviation, CI = confidence interval, ZA = zoledronic acid, LBP = low back pain.
*ANCOVA: Difference between follow-up and baseline, treatment effect adjusted for baseline value.
aOne subject missing at baseline in placebo group and in ZA group, and one subject at 1 month in ZA group.
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ported events mostly consisted of mild to moderate acute
phase reactions, as described in the literature [24,25].
The natural course of MC is not well known. Usually
M1 lesions convert to M2 lesions with time [5], although
small M1 lesions may also normalize [6]. According to
the current view, the persistence of the M1 component
correlates with persistence of symptoms [13,26]. We ob-
served in another study population that symptoms per-
sisted in almost one third of patients over a two-year
follow-up, and that this persistence of symptoms was re-
lated to the persistence of the M1 component (Järvinen,
unpublished observation). It is interesting to evaluate
the course of symptoms in relation to changes in the M1
component on MRI in the current study population.The current theories on the pathomechanisms of MC
include discogenic inflammation [27] and low-grade bac-
terial infection [28]. The bacterial infection theory was
supported by a recent demonstration of the presence of
anaerobic bacteria in lumbar disc herniation in 80% of the
new M1 changes [29], and by the positive results of a trial
with antibiotic treatment [16]. On the other hand, in an-
other Danish study, no anaerobic bacteria were found in
biopsies from vertebrae with M1 lesions [30].
The suggested role of discogenic inflammation is based
on the observation that the cartilaginous endplates of pa-
tients with M1 contained more tumour necrosis factor
(TNF) immunoreactive cells than those of patients with
M2 changes or with normal endplates [27]. Intradiscal
glucocorticoid injection is therefore a logical treatment
Table 3 Health-related quality of life assessed using RAND-36 at baseline, one month and 12 months according to
treatment group and between group comparisons of difference from baseline to one month and 12 months
Mean (SD) original values Mean (SD) change Unadjusted analyses Adjusted analyses
ZA Placebo ZA Placebo Difference P Difference P*
n = 20 n = 20 (95% CI) (95% CI)
Total RAND-36
Baseline 50 (8) 50 (7)
1 month 51 (8) 49 (8) 0.6 (6.4) −0.6 (5.0) 1.2 (−3 to 5) 0.530 1.3 (−3 to 5) 0.477
12 months 51 (8) 49 (9) 1.0 (8.7) −1.0 (5.9) 2.1 (−3 to 7) 0.378 2.2 (−2 to 7) 0.314
Physical component
Baseline 52 (8) 48 (8)
1 month 52 (9) 48 (8) 0.1 (8.6) −0.1 (5.5) 0.3 (−4 to 5) 0.897 1.3 (−3 to 6) 0.554
12 months 52 (8) 48 (2) 0.3 (10) −0.3 (6.5) 0.7 (−5 to 6) 0.808 2.1 (−3 to 7) 0.405
Mental component
Baseline 49 (9) 51 (8)
1 month 50 (9) 50 (9) 1.0 (6.1) −1.0 (5.6) 2.0 (−2 to 6) 0.286 1.6 (−2 to 5) 0.396
12 months 51 (9) 49 (9) 1.8 (9.0) −1.8 (6.7) 3.5 (−2 to 9) 0.167 2.7 (−2 to 7) 0.261
SD = standard deviation, CI = confidence interval, ZA = zoledronic acid.
*ANCOVA: Difference between follow-up and baseline, treatment effect adjusted for baseline value.
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lished case studies on intradiscal steroids into discs with
M1 show improvement in symptoms in the short term
[31,32] and even normalization of M1 changes in MRI
[32]. Similarly, in some cases patients with M1 had a
greater medium-term improvement in disability when
treated with epidural steroid injections [33].
Segmental instability has also been claimed to cause MC
[7]. Two small case studies among patients with chronicTable 4 Adverse events
Adverse events ZA Placebo
n = 20 n = 20
Participants with at least one adverse event 19 (95%) 7 (35%)
Acute phase reaction






Elevated CRP 1 0
Serious adverse events
Prevalence of at least one serious adverse event 1 0
At least one non-elective hospital admission 1 0
Death 0 0
ZA = zoledronic acid.LBP showed that patients with M1 changes benefitted
from instrumented fusion [4,34]. The presence of MC did
not negatively influence the outcome of total lumbar disc
replacement among patients with degenerative disc dis-
ease [35].
Bisphosphonates (BPs) are synthetic analogues of the
endogenous bone mineralization regulators, pyrophos-
phates, and have shown to be potent inhibitors of osteo-
clast activity [36]. Nitrogen-containing bisphosphonates,
such as ZA, inhibit farnesyl diphosphonate synthase and
block prenylation of guanosine triphosphate-binding pro-
tein [37], control osteoblastic proliferation and differenti-
ation [38], modulate osteoblast production of extracellular
matrix proteins, regulate the secretion of several cytokines
and growth factors, and enhance the proliferation and
maturation of bone marrow stromal cells into the osteo-
blastic lineage [39]. Bisphosphonates not only inhibit
osteoclasts; it has also been demonstrated that they
suppress the secretion of proinflammatory cytokines
such as interleukin 1 (IL-1), TNF-α and IL-6 [40]. Clo-
dronate, a first-generation bisphosphonate, has shown
to reduce synovial levels of prostaglandin E2 [41]. The
positive trends observed in our study may partially be
due to the general ability of bisphosphonates to regulate
bone turnover by suppressing osteoclast activity or to
direct anti-inflammatory effects.
Previous studies have shown that RA patients treated
with ZA presented fewer new bone-erosions and less fre-
quently progressing bone oedema in MRI [42]. Among pa-
tients with psoriatic arthritis, ZA reduced the progression
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activity, while ZA had no effect on the progression of ero-
sions [19]. Similarly, pamindronate has been found to be
effective in patients with ankylosing spondylitis refractory
to NSAIDs [43]. Bisphosphonates are generally considered
safe in various indications [37]. Our preliminary results
are encouraging as, in addition to the significant effect in
LBP intensity at one month, there was a noteworthy de-
crease in the use of NSAIDs in the ZA group at one year.
The higher degree of NSAID use at one year in the pla-
cebo group probably dilutes the one-year treatment differ-
ence in the primary outcome. This is a clinically relevant
finding as long-term chronic use of NSAIDs may increase
the risk of gastrointestinal side-effects and cardiovascular
events, which may be avoided with the use of ZA.
The strength of our study is the randomized trial de-
sign. Further strengths include complete follow-up with
no drop-outs and 100% adherence as the medication
was given intravenously. Moreover, intravenously admin-
istered bisphosphonates may have greater treatment ef-
fects than oral bisphosphonates [44].
However, some limitations of our study should also be
discussed. The small sample size of this pilot study is
inadequate to demonstrate clinically relevant changes in
the outcomes. However, despite the small sample a
favourable trend in the ZA group was observed for most
of the outcomes. However, due to multiple testing, the
significance levels of secondary outcomes must be inter-
preted with caution. We did no a priori power calcula-
tions due to the lack of any previous data on the efficacy
of ZA in the studied indication. The patients were well
informed of possible adverse effects; this may have con-
tributed to a large amount of reports of acute phase re-
action symptoms. Some of the main determinants of the
risk of acute phase reactions include younger age and
higher number of circulating inflammatory cytokines
and lymphocytes such as gammadelta cells [24]. The pa-
tients, the study nurse, the medical team in charge of
the patient, the physician performing the assessments
and infusion, and the statistician performing the analyses
were all blinded to the allocation. However, the high in-
cidence of acute phase reaction symptoms in the ZA
group may have revealed the concealment to some pa-
tients. Unfortunately, we did not evaluate the patients’
perception of the nature of the treatment they had re-
ceived. Therefore pre-infusion prophylaxis treatment
was assigned to all patients and the observed higher
incidence of post-infusion symptoms was an expected
finding in the ZA group. However, some patients in the
control group also experienced acute phase reactions.
Conclusions
To our knowledge, this is the first randomized con-
trolled trial to investigate bisphosphonates in chronic,non-specific LBP. The improvement in the intensity of
LBP was greater with a single intravenous infusion of
5 mg ZA compared to placebo at one month. We believe
that ZA is an interesting therapeutic alternative for this
common condition, which is difficult to treat effectively
with conservative treatment approaches [17]. We acknow-
ledge that ZA should only be reserved for patients with
severe disabling LBP, with confirmed MC in MRI, and
when symptoms are not adequately controlled with pain
medication and physiotherapy. Although the results are
encouraging, larger studies are required to prove the effi-
cacy of ZA in patients with LBP due to MC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors were involved in drafting the article or revising it critically and
interpreting the results. KK wrote the first drafts of the manuscript with the
guidance of JK. MH managed the data analyses. All authors approved the
final version for publication.
Acknowledgments
The authors would like to thank Dr. Päivi Paldánius, Director Global Medical
Affairs, of Novartis Pharma AG for linguistic comments and zoledronic
acid-related discussions. We are also grateful to Novartis Pharma AG for the
financial support and medications. We thank Adjunct Professor Antti
Malmivaara, National Institute for Health and Welfare, Centre for Health and
Social Economics, Helsinki; Adjunct Professor Simo Taimela, University of
Helsinki; and Professor Paul Knekt, National Institute for Health and Welfare,
Helsinki, for their comments on statistical analyses.
Financial support
Novartis Pharma provided investigational medications for the study, and
supported the conduct of the trial (<10 000$). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Author details
1Medical Research Center Oulu, Oulu University Hospital and University of
Oulu, Oulu, Finland. 2Institute of Diagnostics, Department of Diagnostic
Radiology, Oulu University Hospital, Oulu, Finland. 3Department of Psychiatry,
Oulu University Hospital, Oulu, Finland. 4Rehabilitation Unit, Oulu Healthcare
Centre, Oulu, Finland. 5ORTON Orthopaedic Hospital, Helsinki, Finland.
6Health and Work Ability, and Disability Prevention Centre, Finnish Institute
of Occupational Health, Oulu, Finland. 7Institute of Clinical Medicine,
Department of Physical and Rehabilitation Medicine, University of Oulu, PL
5000, 90014 Oulu, Finland.
Received: 4 November 2013 Accepted: 24 February 2014
Published: 4 March 2014
References
1. Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR: Degenerative disk
disease: assessment of changes in vertebral body marrow with MR
imaging. Radiology 1988, 166(1 Pt 1):193–199.
2. Kuisma M, Karppinen J, Haapea M, Lammentausta E, Niinimäki J, Tervonen
O: Modic changes in vertebral endplates: a comparison of MR imaging
and multislice CT. Skeletal Radiol 2009, 38(2):141–147.
3. Braithwaite I, White J, Saifuddin A, Renton P, Taylor BA: Vertebral end-plate
(Modic) changes on lumbar spine MRI: correlation with pain
reproduction at lumbar discography. Eur Spine J 1998, 7(5):363–368.
4. Vital JM, Gille O, Pointillart V, Pedram M, Bacon P, Razanabola F, Schaelderle
C, Azzouz S: Course of Modic 1 six months after lumbar posterior
osteosynthesis. Spine 2003, 28(7):715–720.
5. Kuisma M, Karppinen J, Niinimäki J, Kurunlahti M, Haapea M, Vanharanta H,
Tervonen O: A three-year follow-up of lumbar spine endplate (Modic)
changes. Spine (Phila Pa 1976) 2006, 31(15):1714–1718.
Koivisto et al. BMC Musculoskeletal Disorders 2014, 15:64 Page 8 of 9
http://www.biomedcentral.com/1471-2474/15/646. Jensen TS, Bendix T, Sorensen JS, Manniche C, Korsholm L, Kjaer P:
Characteristics and natural course of vertebral endplate signal (Modic)
changes in the Danish general population. BMC Musculoskelet Disord 2009,
10:81.
7. Toyone T, Takahashi K, Kitahara H, Yamagata M, Murakami M, Moriya H:
Vertebral bone-marrow changes in degenerative lumbar disc disease. An
MRI study of 74 patients with low back pain. J Bone Joint Surg (Br) 1994,
76(5):757–764.
8. Kjaer P, Leboeuf-Yde C, Korsholm L, Sorensen JS, Bendix T: Magnetic reson-
ance imaging and low back pain in adults: a diagnostic imaging study
of 40-year-old men and women. Spine 2005, 30(10):1173–1180.
9. Kuisma M, Karppinen J, Niinimäki J, Ojala R, Haapea M, Heliovaara M,
Korpelainen R, Taimela S, Natri A, Tervonen O: Modic changes in endplates
of lumbar vertebral bodies: prevalence and association with low back
and sciatic pain among middle-aged male workers. Spine 2007,
32(10):1116–1122.
10. Hancock M, Maher C, Macaskill P, Latimer J, Kos W, Pik J: MRI findings are
more common in selected patients with acute low back pain than
controls? Eur Spine J 2012, 21(2):240–246.
11. Jensen TS, Karppinen J, Sorensen JS, Niinimäki J, Leboeuf-Yde C: Vertebral
endplate signal changes (Modic change): a systematic literature review
of prevalence and association with non-specific low back pain. Eur Spine
J 2008, 17(11):1407–1422.
12. Mitra D, Cassar-Pullicino VN, McCall IW: Longitudinal study of vertebral
type-1 end-plate changes on MR of the lumbar spine. Eur Radiol 2004,
14(9):1574–1581.
13. Kääpä E, Luoma K, Pitkaniemi J, Kerttula L, Grönblad M: Correlation of size
and type of modic types 1 and 2 lesions with clinical symptoms: a
descriptive study in a subgroup of patients with chronic low back pain
on the basis of a university hospital patient sample. Spine (Phila Pa 1976)
2012, 37(2):134–139.
14. Wilkens P, Scheel IB, Grundnes O, Hellum C, Storheim K: Prognostic factors
of prolonged disability in patients with chronic low back pain and
lumbar degeneration in primary care: a cohort study. Spine (Phila Pa
1976) 2013, 38(1):65–74.
15. Keller A, Boyle E, Skog TA, Cassidy JD, Bautz-Holter E: Are Modic changes
prognostic for recovery in a cohort of patients with non-specific low
back pain? Eur Spine J 2012, 21(3):418–424.
16. Albert HB, Sorensen JS, Christensen BS, Manniche C: Antibiotic treatment
in patients with chronic low back pain and vertebral bone edema
(Modic type 1 changes): a double-blind randomized clinical controlled
trial of efficacy. Eur Spine J 2013, 22(4):697–707.
17. Jensen RK, Leboeuf-Yde C, Wedderkopp N, Sorensen JS, Manniche C: Rest
versus exercise as treatment for patients with low back pain and Modic
changes. A randomized controlled clinical trial. BMC Med 2012, 10:22.
18. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C,
Visser M, Harris TB, Wang BW, Kritchevsky SB, Health, Aging and Body
Composition Study: The relationship of antiresorptive drug use to
structural findings and symptoms of knee osteoarthritis. Arthritis Rheum
2004, 50(11):3516–3525.
19. McQueen F, Lloyd R, Doyle A, Robinson E, Lobo M, Exeter M, Taylor WJ,
Jones P, Reid IR, Dalbeth N: Zoledronic acid does not reduce MRI erosive
progression in PsA but may suppress bone oedema: the Zoledronic Acid
in Psoriatic Arthritis (ZAPA) Study. Ann Rheum Dis 2011, 70(6):1091–1094.
20. Laslett LL, Dore DA, Quinn SJ, Boon P, Ryan E, Winzenberg TM, Jones G:
Zoledronic acid reduces knee pain and bone marrow lesions over
1 year: a randomised controlled trial. Ann Rheum Dis 2012,
71(8):1322–1328.
21. Fairbank JC, Pynsent PB: The oswestry disability index. Spine (Phila Pa 1976)
2000, 25(22):2940–2952. discussion 2952.
22. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey
(SF-36) I. Conceptual framework and item selection. Med Care 1992,
30(6):473–483.
23. Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C,
Felson DT, Hajjaj-Hassouni N, Hochberg M, Logeart I, Matucci-Cerinic M,
van de Laar M, van der Heijde D, Dougados M: Minimum clinically
important improvement and patient acceptable symptom state in pain
and function in rheumatoid arthritis, ankylosing spondylitis, chronic
back pain, hand osteoarthritis, and hip and knee osteoarthritis: results
from a prospective multinational study. Arthritis Care Res (Hoboken) 2012,
64(11):1699–1707.24. Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D:
Circulating gammadelta T cells and the risk of acute-phase response
after zoledronic acid administration. J Bone Miner Res 2012,
27(1):227–230.
25. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM: Characterization of
and risk factors for the acute-phase response after zoledronic acid. J Clin
Endocrinol Metab 2010, 95(9):4380–4387.
26. Jensen RK, Leboeuf-Yde C, Wedderkopp N, Sorensen JS, Jensen TS,
Manniche C: Is the development of Modic changes associated with
clinical symptoms? A 14-month cohort study with MRI. Eur Spine J 2012,
21(11):2271–2279.
27. Ohtori S, Inoue G, Ito T, Koshi T, Ozawa T, Doya H, Saito T, Moriya H,
Takahashi K: Tumor necrosis factor-immunoreactive cells and PGP
9.5-immunoreactive nerve fibers in vertebral endplates of patients with
discogenic low back Pain and Modic Type 1 or Type 2 changes on MRI.
Spine 2006, 31(9):1026–1031.
28. Albert HB, Kjaer P, Jensen TS, Sorensen JS, Bendix T, Manniche C: Modic
changes, possible causes and relation to low back pain. Med Hypotheses
2008, 70(2):361–368.
29. Albert HB, Lambert P, Rollason J, Sorensen JS, Worthington T, Pedersen MB,
Norgaard HS, Vernallis A, Busch F, Manniche C, Elliott T: Does nuclear tissue
infected with bacteria following disc herniations lead to Modic changes
in the adjacent vertebrae? Eur Spine J 2013, 22(4):690–696.
30. Wedderkopp N, Thomsen K, Manniche C, Kolmos HJ, Secher Jensen T,
Leboeuf Yde C: No evidence for presence of bacteria in modic type I
changes. Acta Radiol 2009, 50(1):65–70.
31. Fayad F, Lefevre-Colau MM, Rannou F, Quintero N, Nys A, Mace Y,
Poiraudeau S, Drape JL, Revel M: Relation of inflammatory modic changes
to intradiscal steroid injection outcome in chronic low back pain.
Eur Spine J 2007, 16(7):925–931.
32. Nguyen C, Benichou M, Revel M, Poiraudeau S, Rannou F: Association of
accelerated switch from vertebral end-plate Modic I to Modic 0 signal
changes with clinical benefit of intradiscal corticosteroid injection for
chronic low back pain. Arthritis Rheum 2011, 63(9):2828–2831.
33. Buttermann GR: The effect of spinal steroid injections for degenerative
disc disease. Spine J 2004, 4(5):495–505.
34. Esposito P, Pinheiro-Franco JL, Froelich S, Maitrot D: Predictive value of MRI
vertebral end-plate signal changes (Modic) on outcome of surgically
treated degenerative disc disease. Results of a cohort study including 60
patients. Neurochirurgie 2006, 52(4):315–322.
35. Siepe CJ, Mayer HM, Wiechert K, Korge A: Clinical results of total lumbar
disc replacement with ProDisc II: three-year results for different
indications. Spine (Phila Pa 1976) 2006, 31(17):1923–1932.
36. Hughes DE, MacDonald BR, Russell RG, Gowen M: Inhibition of osteoclast-
like cell formation by bisphosphonates in long-term cultures of human
bone marrow. J Clin Invest 1989, 83(6):1930–1935.
37. Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT: Safety and
tolerability of zoledronic acid and other bisphosphonates in
osteoporosis management. Drug Healthc Patient Saf 2010, 2:121–137.
38. Ebert R, Zeck S, Krug R, Meissner-Weigl J, Schneider D, Seefried L, Eulert J,
Jakob F: Pulse treatment with zoledronic acid causes sustained commit-
ment of bone marrow derived mesenchymal stem cells for osteogenic
differentiation. Bone 2009, 44(5):858–864.
39. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash
HE, Shanbhag AS: Effects of bisphosphonates on proliferation and
osteoblast differentiation of human bone marrow stromal cells.
Biomaterials 2005, 26(34):6941–6949.
40. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J: Effect of liposomal and
free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion
from RAW 264 cells in vitro. Pharm Res 1995, 12(6):916–922.
41. Cocco R, Tofi C, Fioravanti A, Nerucci F, Nannipieri F, Zampieri A, Rosini S,
Marcolongo R: Effects of clodronate on synovial fluid levels of some
inflammatory mediators, after intra-articular administration to patients
with synovitis secondary to knee osteoarthritis. Boll Soc Ital Biol Sper 1999,
75(11–12):71–76.
42. Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O’Connor
PJ, Grainger AJ, Emery P: Preliminary evidence for a structural benefit of
the new bisphosphonate zoledronic acid in early rheumatoid arthritis.
Arthritis Rheum 2006, 54(5):1410–1414.
43. Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B,
Aaron S, Russell AS: Clinical and radiological amelioration of refractory
Koivisto et al. BMC Musculoskeletal Disorders 2014, 15:64 Page 9 of 9
http://www.biomedcentral.com/1471-2474/15/64peripheral spondyloarthritis by pulse intravenous pamidronate therapy.
J Rheumatol 2001, 28(1):144–155.
44. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F,
Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J,
Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF,
Cummings SR, HORIZON Pivotal Fracture Trial: Once-yearly zoledronic acid
for treatment of postmenopausal osteoporosis. N Engl J Med 2007,
356(18):1809–1822.
doi:10.1186/1471-2474-15-64
Cite this article as: Koivisto et al.: Efficacy of zoledronic acid for chronic
low back pain associated with Modic changes in magnetic resonance
imaging. BMC Musculoskeletal Disorders 2014 15:64.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
